Showing results (121-130 of 258) with videos related to
Sort By:
Pageof 26
Molecular Cell|January 28, 2014
Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitorsMehdi Mollapour, Dimitra Bourboulia, Kristin Beebe, et al.Medical Oncology (Northwood, London, England)|April 27, 2017
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancerBryan Oronsky, Carolyn M Ray, Alexander I Spira, et al.Journal of Neurochemistry|October 25, 2006
PC12 cells regulate inducible cyclic AMP (cAMP) element repressor expression to differentially control cAMP response element-dependent transcription in response to nerve growth factor and cAMPJay H Chang, Deepika Vuppalanchi, Erna van Niekerk, et al.Journal of the National Cancer Institute|April 4, 2002
Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228Xiaodan Yu, Z Sheng Guo, Monica G Marcu, et al.Plos One|August 23, 2012
Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolismCéline Douarre, Carole Sourbier, Ilaria Dalla Rosa, et al.Oncotarget|February 2, 2013
TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cellsDimitra Bourboulia, HuiYing Han, Sandra Jensen-Taubman, et al.Molecular Cancer Therapeutics|May 14, 2004
Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activityEdward G Mimnaugh, Wanping Xu, Michele Vos, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2018
Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase InhibitorsSai-Wen Tang, Anish Thomas, Junko Murai, et al.Blood|May 11, 2013
Adult T-cell leukemia cells overexpress Wnt5a and promote osteoclast differentiationMarcia Bellon, Nga Ling Ko, Min-Jung Lee, et al.Oncoimmunology|December 22, 2016
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostatYusuke Tomita, Min-Jung Lee, Sunmin Lee, et al.Pageof 26